The estimated Net Worth of Gil M Labrucherie is at least $11.3 Milione dollars as of 15 May 2022. Mr. Labrucherie owns over 17,448 units of Nektar Therapeutics stock worth over $391,131 and over the last 18 years he sold NKTR stock worth over $3,408,846. In addition, he makes $7,488,840 as Chief Financial Officer, Chief Operating Officer e Senior Vice President at Nektar Therapeutics.
Gilbert has made over 50 trades of the Nektar Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 17,448 units of NKTR stock worth $68,920 on 15 May 2022.
The largest trade he's ever made was exercising 200,000 units of Nektar Therapeutics stock on 2 March 2017 worth over $1,340,000. On average, Gilbert trades about 16,501 units every 34 days since 2007. As of 15 May 2022 he still owns at least 312,905 units of Nektar Therapeutics stock.
You can see the complete history of Mr. Labrucherie stock trades at the bottom of the page.
Gilbert M. Labrucherie J.D. serves as Chief Financial Officer, Chief Operating Officer, Senior Vice President of the Company. Mr. Labrucherie has served as our Senior Vice President, Chief Financial Officer since June 2016, and added the role of Chief Operating Officer in October 2019. Mr. Labrucherie served as our Vice President, Corporate Legal from October 2005 through April 2007 and served as our Senior Vice President, General Counsel and Secretary from April 2007 through June 2016 when he was promoted to Senior Vice President and Chief Financial Officer. From October 2000 to September 2005, Mr. Labrucherie was Vice President of Corporate Development at E2open. While at E2open, Mr. Labrucherie was responsible or global corporate alliances and merger and acquisitions. Prior to E2open, he was the Senior Director of Corporate Development at AltaVista Company, an Internet search company, where he was responsible for strategic partnerships and mergers and acquisitions. Mr. Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati, P.C. Mr. Labrucherie received his J.D. from the Berkeley Law School and his B.A. from the University of California Davis.
As the Chief Financial Officer, Chief Operating Officer e Senior Vice President of Nektar Therapeutics, the total compensation of Gilbert Labrucherie at Nektar Therapeutics is $7,488,840. There are 2 executives at Nektar Therapeutics getting paid more, with Jonathan Zalevsky having the highest compensation of $39,242,200.
Gilbert Labrucherie is 48, he's been the Chief Financial Officer, Chief Operating Officer e Senior Vice President of Nektar Therapeutics since 2019. There are 14 older and 4 younger executives at Nektar Therapeutics. The oldest executive at Nektar Therapeutics is Dr. Brian L. Kotzin, 72, who is the Sr. VP of Clinical Devel. & Head of Immunology.
Gil's mailing address filed with the SEC is C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158.
Over the last 21 years, insiders at Nektar Therapeutics have traded over $57,608,493 worth of Nektar Therapeutics stock and bought 90,000 units worth $1,628,550 . The most active insiders traders include Howard W Robin, Gil M Labrucherie e John Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $36,648. The most recent stock trade was executed by Jonathan Zalevsky on 19 August 2024, trading 6,866 units of NKTR stock currently worth $8,788.
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Nektar Therapeutics executives and other stock owners filed with the SEC include: